SAMSUNG BIOLOGICS announced on the 13th that it earned an “A+” rating in both the environmental and social categories and an “A” rating in the governance category in the 2026 KCGS ESG evaluation. Its overall rating improved as its scores rose across all categories.
KCGS evaluates the ESG management performance of major domestic companies annually and assigns one of seven grades, ranging from S to D. This year, it evaluated a total of 1,087 companies, including 1,020 listed firms. No company received the top-tier S grade, while 18 companies, including SAMSUNG BIOLOGICS, received an A+ grade. The evaluation results are used by institutional investors to assess corporate risk and by the Korea Exchange to select constituents for its ESG index.
SAMSUNG BIOLOGICS explained that it was recognized in the environmental category for setting and disclosing greenhouse gas emission targets, as well as for its efforts to reduce greenhouse gas emissions and water consumption in the product manufacturing process. In the social category, improvements to its human rights management system and expanded disclosures regarding fair trade education were positively evaluated, while in the governance category, enhanced transparency in the operations of the board of directors and the audit committee were recognized.
The company has also received ESG ratings from international rating agencies. This month, it earned the highest rating in Sustainalytics’ ESG risk assessment, and last September, it received an “A” rating in Morgan Stanley Capital International’s (MSCI) ESG assessment.
John Lim, CEO of SAMSUNG BIOLOGICS, stated, “As the KCGS evaluation serves as a benchmark for responsible investment among domestic institutional investors, this achievement will serve as an opportunity to solidify our ESG risk management capabilities and market trust.” He added, “We will continue to enhance stakeholder trust and contribute to the long-term growth of corporate value through transparent and responsible ESG management.”
